Group 1 - The company held a half-year performance briefing on September 17, 2025, via the Shanghai Stock Exchange Roadshow Center [1] - Key executives, including the chairman and president, participated in the briefing and engaged with investors through online interaction [1] - The company is actively promoting a small-scale rapid refinancing through a simplified procedure for targeted issuance of shares, with a financing cap of RMB 300 million [2][5] Group 2 - The company received authorization from its shareholders to issue shares not exceeding 20% of the net assets as of the end of the previous year, with the authorization valid until the next annual shareholders' meeting [2] - The company is focusing on enhancing its core business and exploring new opportunities in the health and judicial IVD sectors, driven by high-tech development [5][7] - The company is implementing measures to strengthen internal controls over accounts receivable and reduce bad debt risks, including customer credit assessments and regular reconciliations [9][10]

Group 1: General Information - The research object is Guofa Co., Ltd., belonging to the pesticide and veterinary medicine industry, and the reception time was September 17, 2025 [17] - The company's reception staff included the company's chairman Jiang Ye, director and president Zhang Xiaowei, director, vice - president and CFO Yin Zhibo, director, vice - president and board secretary Li Yong, and independent director Song Xiaofang [17] Group 2: Research Institutions - The research institutions mainly include investors and others [20] Group 3: Key Points from Company Responses Response to Question 1 (Regrading private placement and stock price) - The company is conducting a "small - scale and fast - track" private placement, a simplified process for specific - object share issuance. The 2024 annual general meeting authorized the board to issue shares with a financing limit of no more than 300 million yuan and no more than 20% of the net assets at the end of the previous year, valid until the 2025 annual general meeting [24][25] - The company is actively promoting the private placement, and the specific implementation time will be announced later. Directors Wu Peicheng and Chairman Jiang Ye have completed share - increasing plans of 381,500 shares and 4.8049 million shares respectively [25] - The company will focus on its main business, enhance internal value, and implement a dual - drive strategy of internal growth and external expansion in the big - health and judicial IVD fields [26] Response to Question 2 (Regarding the board meeting in June) - The company's information disclosure media are "Shanghai Securities News", "China Securities Journal", "Securities Times", "Securities Daily" and the Shanghai Stock Exchange website, and the information should be based on the announcements of these media [26] Response to Question 3 (Regarding AI and computing power business) - The company's strategy is to lead with high - tech, focus on its main business in Guangxi. It is synchronously strengthening its main business and exploring technological innovation, and is open to mergers and acquisitions [26][27] Response to Question 4 (Regarding reducing bad - debt risks of accounts receivable) - The company will strengthen internal control, including revising and improving relevant management systems and designating responsible persons for collection [27] - It will conduct customer credit assessments, formulate credit policies and credit limits accordingly [27] - Regularly conduct aging analysis of accounts receivable and adopt different collection strategies based on aging [28] - Conduct regular account reconciliations with customers to ensure consistent records [28] - Resort to legal means for long - overdue accounts and reasonably set aside bad - debt provisions [28]